Clinical Trial Detail

NCT ID NCT03800836
Title A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

triple-receptor negative breast cancer

Therapies

Atezolizumab + Ipatasertib + Paclitaxel

Atezolizumab + Ipatasertib + Nab-paclitaxel

Age Groups: senior adult

No variant requirements are available.